Robert L. Vitti

Ophthalmology

12 Bolton Pl
Port Chester, NY 10573

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.

Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.

Journal: Therapeutic advances in ophthalmology

Published: April 02, 2026

Three-Year Outcomes of Intravitreal Aflibercept versus Laser Therapy for Retinopathy of Prematurity: Interim Analysis of the Efficacy and Safety Outcomes in the FIREFLEYE next Trial.

Three-Year Outcomes of Intravitreal Aflibercept versus Laser Therapy for Retinopathy of Prematurity: Interim Analysis of the Efficacy and Safety Outcomes in the FIREFLEYE next Trial.

Journal: Neonatology

Published: June 13, 2025

Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial.

Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial.

Journal: Japanese journal of ophthalmology

Published: April 28, 2025

Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial.

Intravitreal aflibercept 8 mg in patients from Japan with neovascular age-related macular degeneration: 48-week subgroup analysis of the PULSAR trial.

Journal: Japanese journal of ophthalmology

Published: April 28, 2025

Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.

Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.

Journal: Ophthalmology

Published: March 05, 2025

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial.

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial.

Journal: Ophthalmology

Published: March 05, 2025

Plain-language commentary: 2-year findings from the FIREFLEYE next study looking at how well aflibercept injected into affected eyes in babies with retinopathy of prematurity works and how safe it is compared with laser treatment.

Plain-language commentary: 2-year findings from the FIREFLEYE next study looking at how well aflibercept injected into affected eyes in babies with retinopathy of prematurity works and how safe it is compared with laser treatment.

Journal: Therapeutic advances in ophthalmology

Published: December 12, 2024

Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.

Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.

Journal: Therapeutic advances in ophthalmology

Published: November 27, 2024

Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration.

Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration.

Journal: Therapeutic advances in ophthalmology

Published: November 19, 2024

Clinical Outcomes in Neovascular Age-related Macular Degeneration with Aflibercept 8 mg in the Phase II CANDELA Study.

Clinical Outcomes in Neovascular Age-related Macular Degeneration with Aflibercept 8 mg in the Phase II CANDELA Study.

Journal: Ophthalmology. Retina

Published: November 18, 2024

Longitudinal Changes in Diabetic Retinopathy Severity: Learnings from PANORAMA.

Longitudinal Changes in Diabetic Retinopathy Severity: Learnings from PANORAMA.

Journal: Ophthalmology. Retina

Published: June 12, 2024

Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity: Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE next.

Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity: Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE next.

Journal: JAMA network open

Published: April 30, 2024

Showing 1-12 of 67

Last Updated: 09/26/2026